Hayden E. Klein

Geri Landman, MD, MPH, cofounder and chair of Moonshots for Unicorns, talks about how the lack of government funding for PGAP3 research led her to take it upon herself to work toward a cure for her daughter.

Chase Hendrickson, MD, MPH, Vanderbilt University Medical Center, attributes gaps in continuous glucose monitoring (CGM) prescribing rates to patient demographics, endocrinologists' longer familiarity with the technology, and the availability of ancillary support in endocrine clinics.

Amitkumar Mehta, MD, MBA, associate professor of medicine and director of the lymphoma and chimeric antigen receptor (CAR) T-cell therapy programs, University of Alabama at Birmingham, highlights the need for novel therapy approaches for patients with high-risk mantle cell lymphoma (MCL).

Researchers noted that it remains unclear whether cytomegalovirus (CMV) infection is a specific cause of worsened cancer-related cognitive impairment (CRCI), or if it is a biomarker for immune suppression.

The study also identified similar 12-month outcomes between torsemide and furosemide regardless of heart failure (HF) type.

Plasma ceramides and sphingomyelins with palmitic acid were linked to a 34% and 37% increased risk of sudden cardiac death (SCD) per higher SD of log sphingolipid levels, respectively.

The tool assesses the risk of heart attack, stroke, and, for the first time, heart failure, offering a more comprehensive perspective on cardiovascular health.

According to researchers, the most prevalent risk factors in children with type 1 spinal muscular atrophy (SMA) are hypercalciuria and elevated urine specific gravity.

New research highlighted how aspirin is unnecessary in antithrombotic regimens for patients with advanced heart failure and fully magnetically levitated left ventricular assist devices (LVADs).

An artificial intelligence (AI)–based prediction model correctly predicted outcomes for 78% of patients with high-grade serous ovarian carcinoma, with an accuracy of 80%.

With the recent development of various new treatments, April Armstrong, MD, MPH, discusses the new standards she and other dermatologists hope to set for treating patients with atopic dermatitis (AD).

These new findings are important as α-blockers (ABs) are the most prescribed class of medications for patients with benign prostatic hyperplasia (BPH), but the cardiovascular safety profile of this treatment is not well understood for this patient population.

The strongest associations between diabetes and colorectal cancer risk were observed in participants with a recent diabetes diagnosis and those who had not undergone recent colonoscopy, underscoring the significance of cancer screening.

Natasha Halasa, MD, MPH, Vanderbilt University Medical Center, discusses the most pressing diarrheal illness challenges and successful strategies physicians can use to reduce this burden in patients.

Amitkumar Mehta, MD, MBA, University of Alabama at Birmingham, notes the long-term data and potential curative effects of chimeric antigen receptor (CAR) T-cell therapy, while expressing optimism about bispecific therapy with ongoing evolution and the chance of significant patient responses.

Edward "Ted" Arrowsmith, MD, MPH, medical director for pathways at OneOncology and managing partner at Tennessee Oncology, highlights the need for trust between payers and providers, as well as finding balance in building consistent clinical pathways while prioritizing specific practice needs.

There is a lot of noise in the health care system, and oncologists need to collaborate and decide on common shared goals, said Lucy Langer, MD, MSHS, national medical director of oncology and genomics at UnitedHealthcare.

Leveraging technology intelligently can make the patient-doctor interaction much more seamless and connected, said Samyukta Mullangi, MD, MBA, medical director of oncology at Thyme Care, medical oncologist at Tennessee Oncology.

Peter A. Lio, MD, clinical assistant professor of dermatology and pediatrics at Northwestern University's Feinberg School of Medicine, lists barriers to care for dermatology patients.

Peter A. Lio, MD, clinical assistant professor of dermatology and pediatrics at Northwestern University's Feinberg School of Medicine, describes different methods dermatologists can use to treat atopic dermatitis (AD).

Mona Shahriari, MD, assistant clinical professor of dermatology at Yale University and associate director of clinical trials at Central Connecticut Dermatology, discusses unique challenges dermatologists face when treating patients with skin of color, who may present differently from White patients.

Patient-Centered Oncology Care® (PCOC) 2023 has a diverse group of people coming in to discuss oncology, including payment reform and the future of oncology care, said Lalan Wilfong, MD, The US Oncology Network.

After implementing a multidisciplinary surgical approach, researchers found that use of the new approach, residual disease, and age were all independent predictors of overall and progression-free survival for patients with ovarian cancer.

Results from the OPEB-01/APGOT-OV4 trial highlight the potential benefits of using olaparib, pembrolizumab, and bevacizumab as a triplet maintenance therapy for patients who have responded to chemotherapy after experiencing platinum-sensitive recurrence in ovarian cancer.

Leaders from Every Cure and Moonshots for Unicorns highlight their work toward finding treatments for rare diseases currently without a cure.

April Armstrong, MD, MPH, of University of California, Los Angeles, discussed how recent biologics advancements improved moderate-to-severe atopic dermatitis (AD) treatment.

Mona Shahriari, MD, assistant clinical professor of dermatology at Yale University and associate director of clinical trials at Central Connecticut Dermatology, provides on overview of the treatment landscape in patients with skin of color with plaque psoriasis.

April Armstrong, MD, MPH, of University of California, Los Angeles, gave an overview of her Fall Clinical Dermatology session on treating atopic dermatitis (AD) in patients with diverse skin tones and weighed in on how to address related treatment barriers.

The improvement in quality of life (QOL) seen with use of sacubitril/valsartan for heart failure with preserved ejection fraction (HFpEF) could potentially result in more favorable clinical results.

Interviews highlight the importance of culturally-tailored diabetes education to address health care disparities in the Mexican American community.